Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 19.79%55.98B | 25.38%54.82B | 16.39%213.74B | 22.37%62.77B | 31.16%60.52B | 2.73%46.74B | 7.40%43.72B | 18.70%183.64B | -3.53%51.29B | 26.45%46.14B |
Cost of revenue | 21.25%46.96B | 31.16%47.15B | 15.91%176.12B | 22.98%52.07B | 28.22%49.38B | 6.08%38.73B | 3.90%35.95B | 18.65%151.95B | -3.79%42.34B | 27.86%38.51B |
Gross profit | 12.72%9.03B | -1.34%7.67B | 18.72%37.62B | 19.43%10.7B | 46.01%11.14B | -10.90%8.01B | 27.20%7.78B | 18.99%31.69B | -2.26%8.96B | 19.79%7.63B |
Operating expense | 16.74%7.31B | 20.46%7.04B | 19.75%27.25B | 21.84%8.09B | 25.12%7.05B | 12.29%6.26B | 19.23%5.84B | 18.85%22.75B | 14.67%6.64B | 19.84%5.64B |
Staff costs | ---- | ---- | 15.60%13.37B | ---- | ---- | ---- | ---- | 21.34%11.56B | ---- | ---- |
Depreciation and amortization | ---- | ---- | 36.62%1.3B | ---- | ---- | ---- | ---- | 89.46%953M | ---- | ---- |
-Depreciation | ---- | ---- | 3.28%473M | ---- | ---- | ---- | ---- | 17.14%458M | ---- | ---- |
-Amortization | ---- | ---- | 67.47%829M | ---- | ---- | ---- | ---- | 341.96%495M | ---- | ---- |
Rent and land expenses | ---- | ---- | 7.80%1.45B | ---- | ---- | ---- | ---- | 13.30%1.35B | ---- | ---- |
Other operating expenses | ---- | ---- | 25.15%11.13B | ---- | ---- | ---- | ---- | 12.19%8.89B | ---- | ---- |
Operating profit | -1.66%1.72B | -67.13%636M | 16.09%10.37B | 12.49%2.6B | 105.12%4.08B | -48.74%1.75B | 59.39%1.94B | 19.34%8.94B | -31.36%2.31B | 19.65%1.99B |
Net non-operating interest income (expenses) | -285.19%-104M | -36.36%-90M | -19.52%-251M | -33.33%-80M | -32.20%-78M | 46.00%-27M | -60.98%-66M | -28.83%-210M | -62.16%-60M | -28.26%-59M |
Non-operating interest income | ---- | ---- | 273.33%56M | -28.57%5M | 100.00%4M | ---- | ---- | 7.14%15M | --7M | --2M |
Non-operating interest expense | 54.05%114M | 36.36%90M | 36.44%307M | 26.87%85M | 34.43%82M | 32.14%74M | 60.98%66M | 27.12%225M | 31.37%67M | 32.61%61M |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 95.96%-13M | -52.61%-322M | ||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | 1M | 0 | 31.55%-141M | 32.04%-140M | 0 | -456.76%-206M | -442.11%-206M | 0 | ||
Less:Other special charges | ---- | ---- | -50.00%26M | --25M | --0 | ---- | ---- | 136.36%52M | ---- | ---- |
Less:Write off | ---- | ---- | -25.32%115M | ---- | ---- | ---- | ---- | 926.67%154M | ---- | ---- |
Other non-operating income (expenses) | 946.67%157M | 59.46%59M | -39.10%162M | 3,400.00%70M | -35.48%40M | -79.45%15M | -71.32%37M | -39.68%266M | -97.06%2M | -50.00%62M |
Income before tax | 2.19%1.78B | -68.26%605M | 19.69%10.12B | 41.42%2.43B | 102.66%4.05B | -49.45%1.74B | 46.39%1.91B | 12.57%8.46B | -44.66%1.72B | 14.65%2B |
Income tax | 24.45%794M | -21.06%742M | 27.75%3.77B | 239.44%852M | 111.02%1.34B | -50.77%638M | 22.24%940M | 8.02%2.95B | -84.49%251M | 60.35%635M |
Net income | -10.90%981M | -114.20%-137M | 15.37%6.35B | 7.49%1.58B | 98.90%2.71B | -48.60%1.1B | 81.05%965M | 15.17%5.5B | -1.34%1.47B | 1.19%1.36B |
Net income continuous operations | -10.73%982M | -114.18%-137M | 15.37%6.35B | 7.56%1.58B | 98.75%2.71B | -48.65%1.1B | 81.24%966M | 15.17%5.5B | -1.34%1.47B | 1.19%1.36B |
Noncontrolling interests | 139.22%122M | -850.00%-15M | -10.49%145M | 645.45%82M | -61.54%10M | -42.70%51M | -94.44%2M | 5.88%162M | -15.38%11M | -69.41%26M |
Net income attributable to the company | -18.29%858M | -112.56%-121M | 16.16%6.2B | 2.67%1.5B | 101.95%2.69B | -48.86%1.05B | 94.15%963M | 15.46%5.34B | -1.22%1.46B | 5.96%1.33B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -18.29%858M | -112.56%-121M | 16.16%6.2B | 2.67%1.5B | 101.95%2.69B | -48.86%1.05B | 94.15%963M | 15.46%5.34B | -1.22%1.46B | 5.96%1.33B |
Gross dividend payment | ||||||||||
Basic earnings per share | -18.54%48.76 | -112.62%-6.93 | 15.75%353.61 | 2.44%85.26 | 101.21%153.56 | -49.06%59.86 | 93.21%54.93 | 15.27%305.5 | -1.53%83.23 | 5.81%76.32 |
Diluted earnings per share | -19.53%47.9527 | -112.67%-6.93 | 15.91%352.15 | 2.65%84.96 | 101.50%152.92 | -49.02%59.59 | 93.35%54.68 | 15.44%303.82 | -1.39%82.77 | 5.99%75.89 |
Dividend per share | 0 | 0 | 15.85%106 | 15.85%106 | 0 | 0 | 0 | 15.09%91.5 | 15.09%91.5 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |